For Medicilon, 2025 was a year of steady execution and meaningful progress, strengthening our foundations, expanding our global footprint, and working closely with partners around the world to move innovative medicines forward.

Throughout the year, we continued to integrate discovery, development, and regulatory readiness, connecting early scientific innovation with global clinical and regulatory pathways. Step by step, we worked with our partners to navigate complexity, reduce uncertainty, and advance programs with confidence, growing alongside the industry and leaving tangible results behind.

Over 100 IND Approvals: Turning Capability into Impact

In 2025, Medicilon further refined our end-to-end preclinical services, from protocol design and study execution to data integration and regulatory submission. Over the course of the year, we supported approximately 100 IND approvals, reflecting both the scale and reliability of our delivery.

Many of these programs have entered pivotal clinical stages, progressed toward commercialization, or expanded into global partnerships. Across modalities, we supported dozens of ADC programs and continued to enable innovation in nucleic acid therapeutics, antibodies, cell therapy, and PROTACs, helping diverse pipelines move forward with clarity and speed.

A Strong Compliance Foundation for Global Development

Global drug development demands not only scientific excellence, but also rigorous compliance. In 2025, Medicilon further strengthened its quality systems and alignment with international regulatory standards.

We successfully passed multiple inspections by global regulatory authorities, including FDA on-site re-inspection, PMDA on-site project inspection, and CNAS laboratory re-accreditation. New certifications, including OECD GLP accreditation in Hungary and Mexico and NMPA GLP supplementary certification, expanded our global qualification and reinforced our ability to support regulatory submissions across major markets.

Advancing R&D Through Technology and New Evaluation Paradigms

Medicilon continued to invest in one-stop R&D platforms spanning ADCs, small nucleic acids, PROTACs, peptides, and cell and gene therapies. Our pharmacology portfolio now includes more than 790 in vivo and in vitro models, with ongoing development of advanced systems such as organoids and ophthalmic disease models to meet emerging scientific needs.

At the same time, we actively explored new approach methodologies (NAMs), including AI-enabled drug discovery workflows, in vitro safety assessment, organoid and PDXO models, and PBPK modeling. These efforts reflect our commitment to evolving drug-evaluation paradigms and supporting more predictive, efficient decision-making in early development.

Expanding Global Reach with Local Execution

Globalization remains central to Medicilon’s long-term strategy. In 2025, we deepened our understanding of international markets and continued building localized service capabilities, improving our responsiveness to regional regulatory requirements and client expectations.

As a result, overseas business continued to grow steadily, with an increasing proportion of global projects and repeat collaborations, providing sustained momentum for long-term development.

Connecting with the Industry, Sharing Knowledge Worldwide

Progress in drug development is accelerated through connection and exchange. In 2025, Medicilon participated in nearly 40 international conferences, including AACR 2025, BIO 2025, EUROTOX 2025, and CPHI Korea 2025. These engagements allowed us to stay close to global R&D trends while amplifying the voice of innovation across the global ecosyetem.

Within China and the broader Asia-Pacific region, we joined 25 major industry events, including BIOCHINA 2025 and the CBA-China Annual Conference. We also successfully hosted the second TRPMA-Medicilon Workshop in Taiwan and launched the first stops of our roadshow seminar series, fostering deeper dialogue across the ecosystem.

Trust Earned Through Service and Responsibility

Guided by our philosophy of Innovation Driven, Quality Focused, Medicilon’s work in 2025 was recognized by partners including TANGO, Eluciderm, Yinsight, Insilico, RayThera, and others.

We also contributed to industry standard-setting by co-drafting the Organoid Drug-Toxicity Evaluation Technical Guideline, supporting the advancement of more robust and consistent evaluation frameworks.

In ESG performance, Medicilon achieved an A rating from Wind ESG and received EcoVadis Bronze certification, along with recognition in the 2025 China Pharmaceutical Listed Companies ESG Competitiveness TOP 10 and the ESG Value Transmission Award.

Looking Ahead

Every journey begins with connection.

Every breakthrough comes from going beyond what is known.

Standing at a new starting point, Medicilon remains committed to compliance as a foundation, technology as a core capability, and service quality as a long-term promise. We will continue to strengthen our integrated preclinical R&D platform, deepen global collaboration, and support more innovative programs on their path from concept to clinic.

Together with our partners worldwide, we look forward to carrying more new-drug ambitions forward, and reaching the next horizon of innovation.